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Summary
 
Narrow-band (312 nm) ultraviolet B light (UVB) is a new form of therapy for psoriasis, but its
mechanism of action is unknown. In a bilateral comparison clinical study, daily exposure of
psoriatic plaques to broad-band UVB (290–320 nm) or 312-nm UVB depleted T cells from the
epidermis and dermis of psoriatic lesions. However, 312-nm UVB was significantly more de-
pleting in both tissue compartments. To characterize the mechanism of T cell depletion, assays
for T cell apoptosis were performed on T cells derived from UVB-irradiated skin in vivo and
on T cells irradiated in vitro with 312-nm UVB. Apoptosis was induced in T cells exposed to
50–100 mJ/cm
 
2
 
 of 312-nm UVB in vitro, as measured by increased binding of fluorescein
isothiocyanate (FITC)–Annexin V to CD3
 
1
 
 cells and by characteristic cell size/granularity
changes measured by cytometry. In vivo exposure of psoriatic skin lesions to 312-nm UVB for
1–2 wk also induced apoptosis in T cells as assessed by the terminal deoxynucleotidyl trans-
ferase–mediated dUTP-biotin nick end labeling (TUNEL) reaction in tissue sections, by bind-
ing of FITC–Annexin V to CD3
 
1
 
 T cells contained in epidermal cell suspensions, and by de-
tection of apoptosis-related size shifts of CD3
 
1
 
 cells. Induction of T cell apoptosis could be the
main mechanism by which 312-nm UVB resolves psoriasis skin lesions.
Key words: psoriasis • immunosuppression • T lymphocyte • apoptosis • ultraviolet light
 
P
 
soriasis vulgaris is a chronic inflammatory skin disease
characterized by infiltration of T cells and hyperprolif-
eration of keratinocytes in focal skin areas. In clinical stud-
ies, disease-related pathology is reversed by lymphocyte-
targeted drugs (1–6), whereas in xenotransplant systems,
psoriasis is induced or sustained by intradermal injection of
activated T cells (7, 8). Therefore, psoriasis is mediated by
activated T cells. In the xenotransplant model, an epider-
mal hyperplasia response appears to arise from cytokines
derived from T cells infiltrating into skin (7). These T cells
are probably reacting to a cutaneous antigen, as clonal CD8
 
1
 
T cell populations have been identified (9) and as systemic
administration of the costimulation blocker, CTLA4Ig, re-
verses clinical and pathological disease features (6). Hence,
skin infiltration by activated cutaneous lymphocyte–associ-
ated antigen–positive T cells appears to cause a complex in-
flammatory tissue phenotype that includes (a) the presence of
several types of activated leukocytes in skin lesions—CD4
 
1
 
and CD8
 
1
 
 T cells, neutrophils, and dendritic antigen pre-
senting cells, (b) a diverse array of cytokines produced by
activated leukocytes and keratinocytes, (c) proliferation of
small blood vessels and epidermal keratinocytes, and (d) in-
creased expression of leukocyte-trafficking adhesion mole-
cules, e.g., intercellular adhesion molecule 1 (ICAM-1),
P-selectin, E-selectin, by hyperproliferative endothelial cells
or keratinocytes (10).
Ultraviolet B light (UVB, 290–320 nm) is used as a ther-
apeutic modality for psoriasis and other inflammatory skin
disorders. Recently, a new UVB source which emits
mostly 311/312-nm light (narrow band [NB]-UVB)
 
1
 
 has
been introduced for treatment of psoriasis and other in-
flammatory dermatoses (11–14). UVB irradiation in a vari-
ety of animal and human model systems inhibits cutaneous
delayed-type hypersensitivity responses to haptens (15, 16),
and its therapeutic mechanism in psoriasis has been attrib-
uted to these immunosuppressive properties. Interestingly,
irradiation of psoriatic skin lesions with standard UVB light
 
1
 
Abbreviations used in this paper:
 
 AnV, Annexin V; APC, allophycocyanin;
BB, broad band; FSC, forward scatter; NB, narrow band; PerCP, peridi-
nine chlorophyll protein; PI, propidium iodide; SSC, side scatter;
TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP-biotin
nick end labeling. 
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causes rapid depletion of intraepidermal T cells (17) and in-
duction of Fas ligand on keratinocytes (18). As apoptosis is
induced by in vitro UVB irradiation of T cells, or by incu-
bation of T cells with keratinocytes expressing UVB-
induced Fas ligand, it has been proposed that UVB may
have immunosuppressive effects in psoriasis through induc-
tion of apoptosis in disease-mediating T cells (17, 18). Al-
though cytotoxic effects of UVB on lymphocytes in vivo are
unproven, irradiation of atopic dermatitis skin lesions with
high-dose UVA (the delivered dose is 
 
z
 
1,000-fold higher
than for therapeutic UVB) has produced detectable apop-
tosis in dermal lymphocytes (19). We now report that 311/
312-nm UVB is directly cytotoxic for T cells in vivo in
psoriatic skin lesions. Furthermore, this new UVB source
depletes T cells to a greater extent than broad-band (BB)-
UVB from both epidermis and dermis of affected skin.
 
Materials and Methods
 
Reagents.
 
The following antibodies were used by FACSCali-
bur
 
®
 
 analysis (Becton Dickinson): peridinine chlorophyll protein
(PerCP)– or allophycocyanin (APC)–anti-CD3, PE–anti-CD4,
FITC–anti-CD8 (Becton Dickinson), and isotype mouse IgG
mAbs.
 
NB-UVB Treatment.
 
23 adult patients (16 men and 7 women)
received irradiation with NB-UVB (312 nm, Philips TL01) on
one vertical half of the body and BB-UVB (290–320 nm,
FST72T12) on the other vertical half. Five additional patients re-
ceived NB-UVB on the whole body. The minimum erythema
dose for each patient was established before irradiation. On each
subsequent day, NB- and BB-UVB irradiations were increased
by 15% unless marked erythema developed. Treatment was ter-
minated upon attaining clinical resolution of psoriatic lesions,
typically after 4–5 wk of daily treatment (20).
 
Histopathological Analysis.
 
Skin punch biopsies were taken
from psoriatic lesions of both NB- and BB-UVB–treated sites be-
fore and after UVB treatment. Biopsies were frozen in OCT so-
lution (Miles Diagnostic Division) for histological analysis. Un-
conjugated anti-CD3 mAb was applied to cryosections for 60
min at room temperature. After washing with PBS, bound anti-
body was visualized by the avidin-biotin complex detection sys-
tem (Vectastain ABC; Vector Laboratories, Inc.) with 3-amino-
9-ethylcarbazol as the chromagen. For double staining, alkaline
phosphatase substrate (Vector Laboratories, Inc.) was also used.
Number of CD3
 
1
 
 cells was counted on the image analyzer using
NIH image public domain software. Detection of apoptosis in
tissue sections was performed by the TUNEL (TdT-mediated
dUTP-biotin nick end labeling) reaction as described (17). TdT
(Amersham Pharmacia Biotech) and biotin-16-dUTP (Boeh-
ringer Mannheim) are used for this technique.
 
Psoriatic Epidermal Cell Suspensions.
 
The shave biopsies were
taken from eleven patients immediately before the start of treat-
ment and after 1 and 2 wk of treatment with NB-UVB. The tis-
sue was washed twice with sterile PBS, incubated in PBS with 1
mg/ml gentamicin (Life Technologies) for 1 h at 4
 
8
 
C, washed
twice in PBS, and floated in 0.5% dispase (Sigma Chemical Co.)
overnight at 4
 
8
 
C. The epidermis was removed and teased into a
cell suspension after brief trypsinization.
 
NB-UVB Irradiation In Vitro.
 
Narrow-band fluorescent UVB
lamps (TL01) were used as a light source. PBMCs were prepared
from heparinized venous blood of healthy volunteers by Ficoll
sedimentation and then irradiated in uncovered tissue culture
plates (10
 
6
 
 cells/well) in PBS. After irradiation, they were sus-
pended in RPMI 1640 with 5% heat-inactivated normal human
serum (C-six Diagnostics, Inc.) with antibiotics.
 
Flow Cytometric Detection of T Cell Apoptosis.
 
T cell apoptosis
was detected using FITC–Annexin V (AnV) staining in conjunc-
tion with a membrane integrity probe (propidium iodide [PI]). In
vitro–irradiated PBMCs, or epidermal cell suspensions obtained
from NB-UVB–treated psoriatic lesions, were stained with
APC–anti-CD3 mAb and FITC–AnV (Kamiya Biomedical Co.).
After washing, the cells were stained with PI, and fluorescence
intensity was measured by a four-color FACSCalibur
 
®
 
.
 
Flow Cytometric Phenotyping of T Cells in Psoriatic Lesions.
 
Psoriatic epidermal cell suspensions were stained with selected
mAbs. After washing with PBS/0.1% sodium azide/2% FBS, cells
were fixed with PBS/3.75% formaldehyde and analyzed by flow
cytometry within 1 wk. Flow cytometric analysis was done using
CellQuest software (Becton Dickinson).
 
Results
 
NB-UVB Depletes T Cells From Psoriatic Lesions More than
BB-UVB.
 
Psoriatic plaques in 23 patients were treated
daily with NB-UVB or BB-UVB in a bilateral comparison
study (20). The ability of NB-UVB or BB-UVB to deplete
T cells from psoriatic lesions was studied with CD3 anti-
bodies and quantitative image analysis using immunohis-
tochemistry (Fig. 1 A). Both forms of UVB reduced in-
traepidermal T cells from lesional skin, but quantitative
reductions were greater with NB-UVB (96 vs. 85% reduc-
tion,
 
 P 
 
5 
 
0.01; Fig. 1 B). Reductions in dermal CD3
 
1
 
 cells
were also greater with NB-UVB (54 vs. 29% reduction,
 
 P 
 
,
 
0.01; Fig. 1, A and B). Flow cytometric analysis confirmed
that rapid decreases in the number of CD3
 
1
 
, CD4
 
1
 
, and
CD8
 
1
 
 T cell subsets in psoriatic epidermis occur during the
first 2 wk of treatment (Fig. 1 C).
 
T Cell Apoptosis Is Induced by NB-UVB Irradiation.
 
To
establish the mechanism of T cell depletion from psoriatic
lesions by irradiation, we examined NB-UVB–treated lym-
phocytes for DNA fragmentation and membrane changes
that typify apoptosis. TUNEL reactions showed more apop-
totic cells in NB-UVB–treated psoriatic lesions compared
with contralateral lesions treated with BB-UVB (Fig. 2).
To confirm that apoptotic cells detected in psoriatic tissue
after irradiation were T cells, we performed double staining
(CD3 and TUNEL). Fig. 2 (bottom) shows a psoriatic lesion
taken after 2 wk of daily NB-UVB treatment. TUNEL
 
1
 
 cells
stain red, and CD3
 
1
 
 cells stain blue. Double-stained cells (in-
dicated with arrows) were observed in the treated skin,
whereas no double-positives were noted before treatment.
As detection of apoptotic cells in psoriatic epidermis is
problematic using the current TUNEL method (21), we
used flow cytometry to examine isolated intraepidermal
CD3
 
1
 
 lymphocytes for (a) increased binding of AnV, a
protein which binds to phosphatidyl serine that is expressed
on T cell plasma membranes in early stages of apoptosis;
and (b) forward scatter (FSC) and side scatter (SSC) alter-
ations that typify cytoplasmic shrinkage and organelle com-
paction in T cells undergoing apoptosis. As a control for 
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Figure 1. (A)  Immunohisto-
chemical detection of T cells in
psoriatic lesional skin from two
patients before and after 4 wk of
UVB treatment. Left, untreated
psoriatic lesions; middle, 4-wk
NB-UVB–treated lesions; right,
4-wk BB-UVB–treated lesions
(original magnification: 3100).
(B) Quantitative analysis of T
cell infiltration in psoriatic skin.
Panels show mean numbers of
CD31 cells in the epidermis and
dermis of psoriatic lesional skin
before and after treatment. n 5
23. SE is shown for each mean
value. Cell numbers are ex-
pressed per image analysis field.
(C) Phenotypic characterization
of T cells infiltrating psoriatic
epidermis before and after NB-
UVB treatment. Flow cytomet-
ric analysis was performed on
epidermal suspensions from five
psoriatic patients for phenotyp-
ing of intraepidermal T cells.
Panels display the number of T
cells (and also CD4 or CD8 sub-
set) in psoriatic epidermis during
treatment. The numbers are nor-
malized to per 1,000 keratino-
cytes. Mean percentage is shown
in parentheses. Paired t test was
done. P values: *P , 0.05, **P ,
0.01, ***P , 0.005. 
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these experiments, PBMCs were irradiated with increasing
amounts of NB-UVB (Fig. 3 A). Dual measurement of
AnV binding and membrane integrity with PI makes it
possible to distinguish early (AnV
 
1
 
/PI
 
2
 
) and late stages of
apoptosis (AnV
 
1
 
/PI
 
1
 
). Hence, a flow cytometer with two
lasers and four-color detection was used to simultaneously
assess CD3-APC, AnV–FITC, and PI staining (PE/PerCP
channels) on individual cells. As shown in Fig. 3 A, dose-
and time-dependent increases in binding of AnV to T cells
occurred after exposure of cells to NB-UVB ranging from
25 to 100 mJ/cm
 
2
 
. Cells progressed from an early stage of
apoptosis (AnV
 
1
 
/PI
 
2
 
) to a late stage of apoptosis (AnV
 
1
 
/
PI
 
1
 
) during 20 h after irradiation. Analysis of FSC and SSC
in CD3
 
1
 
 cells showed dose-dependent increases in a size-
shifted population (blue). Cells in this size-shifted popula-
tion are displayed as blue dots in Fig. 3 A, which indicates
that size-shifted cells are mostly AnV
 
1
 
/PI
 
1
 
, or late-stage
apoptotic cells.
Fig. 3 B shows analysis of T cell death in lesional epider-
mis from a psoriatic patient after irradiation with NB-UVB
in vivo. After 2 wk of daily treatment of NB-UVB, 45% of
intraepidermal T cells were AnV
 
1
 
 vs. 14% in unirradiated
psoriatic epidermis (panels for patient 1). Cells in the early
stage of apoptosis (AnV
 
1
 
/PI
 
2
 
) were increased by fourfold
in this patient. The mean value of four patients is listed in
Table I. As shown in panels for patient 2, we also tracked
cytotoxic effects of NB-UVB on intraepidermal T cells of
11 psoriatic patients using flow cytometry with ethidium
homodimer (a vital fluorescent dye) and by examining T
cells for cell shrinkage (reduced FSC signal) and increased
granularity (increased SSC signal), changes that occur in
apoptosis (22). Using ethidium homodimer staining, in-
creased T cell death was detected in 10 out of 11 patients,
and the mean value was 19.6 
 
6 
 
3.25% before treatment and
30.3 
 
6 
 
4.10% after treatment (listed in Table I). Using FSC
and SSC analysis, the percentage of apoptotic T cells in 11
patients was 35.7 
 
6 
 
12.2% before treatment and 56.3 
 
6
 
18.5% after treatment (paired 
 
t
 
 test;
 
 P 
 
, 
 
0.001, Table I).
Hence, three independent assays (AnV binding, membrane
integrity, and cell morphology assays) demonstrate cyto-
toxic effects of NB-UVB on a significant fraction of in-
traepidermal T cells.
Figure 2. TUNEL reactions to sections of psoriatic skin during UVB treatment. Top: left, before treatment; middle, after 2 wk of NB-UVB treat-
ment; right, after 2 wk of BB-UVB treatment (original magnification: 3100). Bottom: double (CD3 and TUNEL) staining on sections of psoriatic skin
from another patient after 2 wk of NB-UVB treatment. TUNEL1 cells stain red (left, original magnification: 3100); CD31 cells stain blue (middle, orig-
inal magnification: 3100); double-positive cells are indicated with arrows (original magnification: 3200). 
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Discussion
 
Paradoxically, the UVB spectrum (290–320 nm) causes
inflammation in irradiated skin (the sunburn reaction),
whereas exposure of inflamed skin to similar amounts of
UV energy resolves a number of immunologically medi-
ated dermatoses. An action spectrum study in patients with
psoriasis established that wavelengths from 290 to 300 nm
produced the sunburn reaction (intense erythema and kera-
tinocyte necrosis) but had no therapeutic benefits, whereas
313-nm UVB showed mostly therapeutic, but minimally
erythemogenic potential (23). Based on this action spec-
trum, a fluorescent UVB source was developed for psoriasis
therapy that delivers 311/312-nm (“narrow-band”) UVB
(11). NB-UVB has been shown to be superior for clearing
psoriasis and other inflammatory disorders compared with
BB-UVB sources that emit over most of the UVB spec-
trum (11, 12, 24). Although BB-UVB produces a wide va-
riety of cellular and immunosuppressive effects in skin (15,
25–29), it has been suggested that the therapeutic effective-
ness in inflammatory skin disorders could be mediated by
the cytotoxic effects of UVB on infiltrating lymphocytes
(17). However, the only direct evidence that UV light can
produce lymphocyte apoptosis in human skin comes from a
Figure 3. Flow cytometric as-
sessment of T cell death induced
by NB-UVB irradiation. All plots
show only CD31 T cells as identi-
fied by FITC-CD3 or APC-CD3
staining. (A) In vitro irradiation
of T cells. Peripheral blood T
cells  were irradiated with increas-
ing amounts of NB-UVB, and
apoptosis was assessed at either 5
or 20 h after irradiation. The top
panels show simultaneous FITC–
AnV and PI staining on the ordi-
nate and abscissa, respectively. The
quadrants of these plots indicate
live cells (AnV2/PI2), early-stage
apoptosis (AnV1/PI2), or late-
stage apoptosis (AnV1/PI1). Re-
sults show dose- and time-depen-
dent increases in AnV1/PI2 and
AnV1/PI1 cell populations. The
bottom panels are plots of FSC
(cell size) and SSC (granularity)
for CD31 cells that are illustrated
in AnV/PI plots of 20-h cells.
Large CD31 cells with minimal
granularity are colored red and
are predominantly live cells as
shown in the panel above (the
same cell population is colored
red in the AnV/PI plot). Smaller
CD31 cells with increased gran-
ularity are colored blue. This
population is apoptotic cells (Ap)
as shown for blue-colored cells
in the AnV/PI plots above. (B)
In vivo irradiation of epidermal
T cells. T cell apoptosis was as-
sessed in epidermal cells obtained
from psoriatic skin. Plots illus-
trate only CD31 cells in the epi-
dermis. The panels of patient 1
quantify apoptosis in intraepider-
mal T cells before treatment or
after 2 wk of daily irradiation
with NB-UVB using the assays
shown in A. The plots for pa-
tient 2 show ethidium homo-
dimer uptake as an alternative
measure of cell death (ethidium
homodimer1 cells are apoptotic
and correspond to size-shifted
[Ap] cells in FSC/SSC plots for
this patient). 
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study of high-dose UVA (320–400 nm) used to treat pa-
tients with atopic dermatitis (19).
Surprisingly, immune-modulating effects of 311–312-nm
UVB have not been studied previously in psoriatic skin or
skin lesions of other inflammatory diseases. The results of this
study show that NB-UVB causes greater depletion of T cells
in psoriatic tissue than BB-UVB, and establish direct cyto-
toxic actions of UVB on T cells infiltrating skin lesions.
The in vivo results are paralleled by in vitro experiments
where exposure of T cells to moderate doses of 312-nm
UVB light induced rapid apoptosis. In fact, given that
 
z
 
10% of UVB energy incident on skin penetrates the epi-
dermis, there is reasonably good agreement between doses
of 312-nm UVB required to kill T cells (50–100 mJ/cm
 
2
 
)
and therapeutic amounts of 312-nm UVB delivered to pso-
riatic lesions (300–1,200 mJ/cm
 
2
 
). The greater effectiveness
of 312-nm UVB in depletion of dermal T cells is probably
related to (a) somewhat deeper penetration of this wave-
length in dermis compared with the composite of wave-
lengths present in BB-UVB sources (30, 31), and (b) the
ability to deliver more Joules of UVB energy with NB-
UVB sources due to a reduction in its burning potential.
These investigations do not define biochemical pathways
mediating the cytotoxic or immunosuppressive effects of
NB-UVB. Previous studies with BB-UVB have suggested
that apoptosis of epidermal T cells might be induced by in-
teraction of Fas on T cells and upregulated Fas ligand on ir-
radiated keratinocytes (18). Although this mechanism could
also pertain to 312-nm UVB, rapid apoptosis was produced
in isolated leukocytes by direct irradiation in vitro with rel-
atively small amounts of UVB (17, 32). Potential molecular
targets of UVB in T cells include p53, which is upregulated
or stabilized after UVB exposure in some cells and can po-
tentially mediate apoptosis in the setting of UVB-induced
DNA damage (33, 34), or calmodulin-dependent protein
kinase II, which is activated after UVB exposure and leads
to activation of AP24, 24-kD apoptotic protease (35, 36).
In addition, low-dose UVB can inactivate signal transducer
and activator of transcription 1 (STAT-1), a critical com-
ponent of signal transduction, which then inhibits gene
transcription (37, 38).
In most cases, direct irradiation of normal skin with
erythemogenic amounts of UVB prevents delayed-type hy-
persensitivity reactions to topical sensitizers. This altered
immune reactivity has been attributed to UVB-induced
depletion of Langerhans cells from epidermis (39). In a
prior study, therapeutic amounts of BB-UVB did not ap-
preciably reduce the abundance of CD1a
 
1
 
 epidermal cells
in lesional psoriatic skin (17). We detected no obvious re-
ductions in CD1a
 
1
 
 cells after irradiation of psoriatic lesions
with NB-UVB (data not shown). Hence, depletion of T
cells from psoriatic lesions appears to be selective for a re-
stricted set of leukocytes. Accordingly, our studies suggest
that the major therapeutic mechanism of UVB light in in-
flammatory dermatoses is a cytotoxic effect on skin-infil-
trating T cells, where the mechanism of death is most likely
through apoptosis.
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Table I.
 
Measurement of Intraepidermal T Cell Apoptosis in 
Psoriatic Skin Treated with NB-UVB by Three Different Flow 
Cytometry–based Assays
 
Measurement in
CD3
 
1
 
 cells
 
*
 
No. of
patients
Pretreat-
ment
Posttreat-
ment
 
%%
 
Apoptotic shift (FSC/SSC) 11 35.7 
 
6
 
 12.2 56.3 
 
6
 
 18.5
 
‡
 
FITC–AnV binding 4 10.8 
 
6
 
 4.17 46.7 
 
6
 
 14.8
 
§
 
Ethidium homodimer uptake 11 19.6 
 
6
 
 3.25 30.3 
 
6
 
 4.10
 
§
 
*
 
All assays were performed with trypsinized epidermal cell suspensions.
An electronic gate was set on T cells labeled with FITC-CD3 (for
ethidium homodimer experiments) or APC-CD3 (for FITC–AnV ex-
periments). The apoptotic shift indicates cell shrinkage and increased
cytoplasmic complexity measured by FSC/SSC as illustrated in Fig. 3.
The table lists mean values for each parameter 
 
6
 
 SD. 
 
P
 
 values: 
 
‡
 
P
 
 ,
0.001, §P , 0.025.717 Ozawa et al.
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